NewsMedicinal CannabisA Golden Ambition For Medical Cannabis Industry?

A Golden Ambition For Medical Cannabis Industry?

-

CREATING standardised medicine is the gold standard for the cannabis industry but the nature of the plant makes this difficult, says a leading expert.

Dr Barbara Pacchetti, of U.K. company EMMAC Life Sciences, speaking at Cannabis Europa, described cannabis as an ‘unconventional medicine’.

“The aim is for standardised medicine, and this would be the peak of Everest. Doctors are not comfortable with anything else, but with cannabis we have the plant’s entourage effect and this leads to a lot of questions and grey areas in relation to variability.

“For pharma companies, isolates are the gold standard, but there is variability with cannabis due to the different cannabinoids, plant strains, the terpenes and the flavonoids and this means we have to do more work to understand this entourage; the genetics.”

Speaking on day one of the the conference, last year, in a debate on ‘Cannabis-Based Medicines’ she said it would initially be difficult to bridge the gap left by a lack of research, due to the prohibition of cannabis over the last 60 years.

And she added: “We are just the beginning to learn and to connect with regulators, the health authorities and this will allow us to make the right cannabis medicines available to the public.”

Dianna Gutierrez, of Spanish firm Linneo Health, agreed there was much research to be done. She said it was looking at selecting different cannabis molecules and products to target different diseases.

She added: “We have to change way we produce, grow and manufacture a medicine and we need the money; huge investment from funds to get the quality of drug we require.”

Aras Azadian, of Canadian company Avicanna, said physicians like to have 

straight-forward medicines they can rely on, and this is a challenge the cannabis industry can rise to.

“They depend on one or two, high-standard products. When prescribing, it’s a case of taking it in stages – crawl, walk, run – but patients may see things differently and want different strains and flowers, for example.

“Patients have become accustomed to having the same level of consistency in their medicines, but the variability of the cannabis plant makes this difficult to achieve. 

“Cannabis medicine needs to have the highest standards; Quality assurance, and standardisation of cannabis medicine is necessary, achievable, and the responsibility of the people in this room.”


Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Industry Concerns Surface Over No 10 Taskforce’s Hemp And Cannabis Proposals

THE initial warm welcome to proposals to make UK cannabinoid regulations a matter for the health authorities - not...

IM Cannabis Clinical Survey Confirms Effectiveness of Proprietary Strains in Alleviating Symptoms of Seven Key Health Conditions

IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC, CSE:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational...

Always Pure Organics Makes £3m Continental Swoop For Leading B2C Hemp And CBD Player

FAST-GROWING UK cannabis wholesaler Always Pure Organics has acquired two Belgian companies - Distribution Legal Hemp and NexGen -...

Little Green Pharma Picks Up Distressed Canadian LP’s Danish Cannabis Asset for £11.6m

AUSTRALIAN company Little Green Pharma has purchased the former Canopy Growth medicinal cannabis cultivation and manufacturing facility in Denmark...

New Era Beckons For Swiss Medical Cannabis Patients After Ten Years In Slow Lane

THE impending change to Switzerland’s medical cannabis laws could see the number of patients receiving treatment rise from 3,000...

How Britain’s Three Crown Dependencies Are Stealing A Cannabis March On the Mainland

FRUSTRATED by the UK Government’s stance the three UK Crown Dependencies of Jersey, Guernsey and the Isle of Man,...

Must read

Industry Concerns Surface Over No 10 Taskforce’s Hemp And Cannabis Proposals

THE initial warm welcome to proposals to make UK...

Little Green Pharma Picks Up Distressed Canadian LP’s Danish Cannabis Asset for £11.6m

AUSTRALIAN company Little Green Pharma has purchased the former...

You might also likeRELATED
Recommended to you